Emcure Pharmaceuticals announced robust financial results for the fiscal year ended March 31, 2026 (FY 2025-26). The company’s revenue from operations grew by 16.6% year-on-year to reach INR 92,035 million, crossing the significant USD 1 billion revenue milestone. Profit After Tax (PAT) saw a substantial increase of 33.1% year-on-year, demonstrating strong operational performance and strategic execution.
Emcure Pharmaceuticals Reports Strong FY 2025-26 Financials
Emcure Pharmaceuticals Limited has declared its financial results for the fiscal year ended March 31, 2026 (FY 2025-26), showcasing a period of significant growth and improved profitability. The company achieved a milestone by surpassing the USD 1 billion revenue mark, with revenue from operations increasing by a healthy 16.6% to INR 92,035 million.
Key Financial Highlights
The company reported a robust performance across key financial metrics. EBITDA margin improved by 80 basis points to 19.4%, driven by enhanced utilization and productivity gains. Profit After Tax (PAT) grew by over 40% year-on-year, reflecting the success of strategic initiatives and disciplined execution. ROCE improved by 170 basis points to 23.7%.
Strategic Growth Drivers
Emcure’s strategic priorities for FY 2026-27 focus on deepening its domestic franchise, scaling global operations, and advancing its innovation pipeline. The company highlighted its strong partnerships and a differentiated global portfolio as key drivers for future growth. Investments in R&D remained strong, with expenditure at 4.2% of revenue, supporting the development of complex injectables, biologics, and advanced delivery systems.
Operational Performance
Operationally, Emcure saw a ~60%+ chronic mix and strengthened its position in Canada as a top 10 generic player. The company also made significant strides in international markets, with revenue from international businesses growing 22.2%. Notable partnerships and acquisitions were completed, bolstering the company’s therapeutic offerings and market presence.
Looking Ahead
The company expressed confidence in its growth outlook for FY 2026-27, targeting low-to-mid teens growth and steady improvement in EBITDA margins. Emcure remains focused on disciplined capital allocation and stronger operating leverage across its businesses.
Source: BSE
